Products
Amostomig Biosimilar Bispecific Antibody (CD47 × PD-L1) for Research
Cat No.: GMP-Bios-INN-1077
Anti-IAP/CD47/MER6/OA3 therapeutic antibody (Pre-made Amostomig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Amostomig (development code BCD-106) is a bispecific antibody targeting CD47 and PD-L1 (CD274). It is developed by Biocad CJSC for solid tumours. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1077-1mg | 1mg | |
| GMP-Bios-INN-1077-10mg | 10mg | |
| GMP-Bios-INN-1077-100mg | 100mg | |
| GMP-Bios-INN-1077-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Amostomig biosimilar, Bispecific mAb, Anti-IAP/CD47/MER6/OA3;PDL1/CD274 Antibody: Anti-CD47/Leukocyte surface antigen CD47/Antigenic surface determinant protein OA3/Integrin-associated protein (IAP) therapeutic antibody |
| INN Name | Amostomig |
| Target | IAP/CD47/MER6/OA3;PDL1/CD274 |
| Format | Bispecific mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Lambda;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I/Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Biocad CJSC |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
